Mechanism Deep Dive / Cellular Signaling
KY19382 (KY-19382) is an experimental indirubin-derived small molecule investigated for modulation of the Wnt/β-catenin pathway. Its follicle findings are preclinical—not evidence of an approved or proven human hair-loss treatment.
How KY19382 affects Wnt/β-catenin signaling
Wnt/β-catenin signaling contributes to hair-follicle development and cycling. The CXXC5 protein can restrain this pathway by interacting with Dishevelled (DVL), an intracellular signaling protein. KY19382 was developed as an inhibitor of the CXXC5–DVL interaction; early discovery work also described effects on GSK-3β, another regulator of β-catenin.
Disrupting a negative feedback interaction can increase β-catenin-associated signaling in a particular experimental system. That does not mean all tissues or doses behave identically. Wnt signaling operates across many biological processes, so the specific cell model and measured endpoint matter.
What the 2021 hair-follicle study actually measured
A 2021 British Journal of Pharmacology study by Ryu and colleagues tested KY19382 in human dermal papilla cells, cultured human hair follicles and mouse models. The authors reported increased Wnt-associated biomarkers, increased elongation of cultured follicles, and changes in mouse hair-regrowth and wound-induced follicle formation assays.
Cultured human follicles are not human clinical trials. The paper’s reported hair-regrowth and neogenesis endpoints were largely from animal models, and these results do not establish safety, effectiveness, appropriate exposure or long-term outcomes in people.
Separate research examined KY19382 in cutaneous wound models, reporting changes in re-epithelialization and marker expression in cultured skin cells and mice. Such findings are mechanistic context, not an indication that KY19382 is a proven wound-healing product. Read the full KY19382 research reference for compound identification and a broader bibliography.
KY19382 vs PP405 vs finasteride: different research pathways
| Compound | Primary pathway under study | Evidence distinction |
|---|---|---|
| KY19382 | CXXC5/DVL, GSK-3β and Wnt/β-catenin signaling | Preclinical cell, organ-culture and mouse research |
| PP405 | Mitochondrial pyruvate carrier and follicle metabolic state | Human investigational trials, including an ongoing Phase 2/3 program |
| Finasteride | 5α-reductase and androgen/DHT metabolism | Clinical evidence for specific studied formulations; formulation-dependent safety |
These compounds are not interchangeable simply because they appear in hair-follicle research searches. Comparing their molecular targets is more informative than ranking them as treatments without head-to-head trials.
KY19382 frequently asked questions
What is the difference between KY and KY19382?
“KY” is ambiguous. This page refers specifically to KY19382, also written KY-19382, the indirubin-derived compound studied in Wnt/β-catenin research.
Is KY19382 a peptide?
No. KY19382 is a synthetic small molecule in the indirubin derivative family, not an amino-acid peptide.
Has KY19382 been proven to regrow hair in humans?
No. The cited follicle findings are from laboratory and animal systems. Cultured human follicle experiments are not evidence of clinical efficacy in people.
Where can I check Disguised Alpha KY19382 batch testing?
Open the COA portal and match the product lot identifier. A certificate documents the tested sample and reported analytical methods, not clinical efficacy.
Primary literature
- Ryu YC et al. (2021). KY19382, a novel activator of Wnt/β-catenin signalling, promotes hair regrowth and hair follicle neogenesis. British Journal of Pharmacology. DOI: 10.1111/bph.15438.
- Yoon et al. (2023). KY19382 accelerates cutaneous wound healing via activation of the Wnt/β-catenin signaling pathway. International Journal of Molecular Sciences. DOI: 10.3390/ijms241411742.
- Disguised Alpha KY19382 research guide — further citations, compound identity, limitations and storage.
Research and editorial disclosure: Disguised Alpha publishes this educational reference and sells some of the research materials mentioned. Findings from independent investigators or drug developers do not establish the identity, performance, safety or therapeutic efficacy of Disguised Alpha formulations. Research-use-only materials are not intended for human or animal administration, diagnosis, prevention or treatment. This page does not provide dosing advice. Source review: October 29, 2026.